ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

January 22, 2022

Study Completion Date

January 22, 2022

Conditions
ALL, ChildhoodMinimal Residual Disease
Interventions
DRUG

Blinatumomab

15 mcg/m2/day for 28 days

Trial Locations (14)

1090

St. Anna Kinderspital, Vienna

Unknown

University Hospital Gasthuisberg (UZ Leuven), Leuven

Motol University Hospital Prague, Prague

Rigshospitalet Copenhagen, Copenhagen

Hôpital Robert Debré, Paris, Paris

Ospedale S. Gerardo Monza, Monza

IRCCS Ospedale Pediatrico Bambino Gesù Roma, Roma

Oslo University Hospital, Oslo

Nicolaus Copernicus University Collegium Medicum, Bydgoszcz

Lublin, Medical Academy, Lublin

University of Medical Sciences Poznan, Poznan

Klinika Transplantacji Szpiku, Wroclaw

University Children's Hospital, Bratislava

Hospital Universitario Vall d'Hebron, Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Prof. Christina Peters

OTHER

NCT04785547 - ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT | Biotech Hunter | Biotech Hunter